Anti-SLC25A34 monoclonal antibody
Pre-made anti-SLC25A34 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to SLC25A34/SLC25A34 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP1675-Ab-1/ GM-Tg-hg-IP1675-Ab-2 | Anti-Human SLC25A34 monoclonal antibody | Human |
| GM-Tg-rg-IP1675-Ab-1/ GM-Tg-rg-IP1675-Ab-2 | Anti-Rat SLC25A34 monoclonal antibody | Rat |
| GM-Tg-mg-IP1675-Ab-1/ GM-Tg-mg-IP1675-Ab-2 | Anti-Mouse SLC25A34 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP1675-Ab-1/ GM-Tg-cynog-IP1675-Ab-2 | Anti-Cynomolgus/ Rhesus macaque SLC25A34 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP1675-Ab-1/ GM-Tg-felg-IP1675-Ab-2 | Anti-Feline SLC25A34 monoclonal antibody | Feline |
| GM-Tg-cang-IP1675-Ab-1/ GM-Tg-cang-IP1675-Ab-2 | Anti-Canine SLC25A34 monoclonal antibody | Canine |
| GM-Tg-bovg-IP1675-Ab-1/ GM-Tg-bovg-IP1675-Ab-2 | Anti-Bovine SLC25A34 monoclonal antibody | Bovine |
| GM-Tg-equg-IP1675-Ab-1/ GM-Tg-equg-IP1675-Ab-2 | Anti-Equine SLC25A34 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP1675-Ab-1/ GM-Tg-hg-IP1675-Ab-2; GM-Tg-rg-IP1675-Ab-1/ GM-Tg-rg-IP1675-Ab-2; GM-Tg-mg-IP1675-Ab-1/ GM-Tg-mg-IP1675-Ab-2; GM-Tg-cynog-IP1675-Ab-1/ GM-Tg-cynog-IP1675-Ab-2; GM-Tg-felg-IP1675-Ab-1/ GM-Tg-felg-IP1675-Ab-2; GM-Tg-cang-IP1675-Ab-1/ GM-Tg-cang-IP1675-Ab-2; GM-Tg-bovg-IP1675-Ab-1/ GM-Tg-bovg-IP1675-Ab-2; GM-Tg-equg-IP1675-Ab-1/ GM-Tg-equg-IP1675-Ab-2 |
| Products Name | Anti-SLC25A34 monoclonal antibody |
| Format | mab |
| Target Name | SLC25A34 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-SLC25A34 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP1675-Ag-1 | Recombinant multi-species S2534/ SLC25A34 protein |
Target information
| Target ID | GM-IP1675 |
| Target Name | SLC25A34 |
| Gene ID | 284723,384071,298606,695610,608629,101081994,515553,100054040 |
| Gene Symbol and Synonyms | Gm1369,SLC25A34 |
| Uniprot Accession | Q6PIV7,Q5XIF9,Q3SZK0 |
| Uniprot Entry Name | S2534_HUMAN,S2534_RAT,S2534_BOVIN |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000162461 |
| Target Classification | N/A |
The target: SLC25A34, gene name: SLC25A34, also named as . SLC25A34 belongs to the SLC25 family of mitochondrial carrier proteins (Haitina et al., 2006 [PubMed 16949250]).[supplied by OMIM, Mar 2008].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

